* . *
  • About
  • Advertise
  • Privacy & Policy
  • Contact
Monday, October 6, 2025
Earth-News
  • Home
  • Business
  • Entertainment
    Charlie Hunnam Reflects on Playing a Serial Killer in Monster: The Ed Gein Story – Yahoo

    Charlie Hunnam Reveals the Dark Challenges of Playing a Serial Killer in Monster: The Ed Gein Story

    “Reba” cast, then and now: See the stars 24 years later (and who’s reunited for another show) – Yahoo

    “Reba” cast, then and now: See the stars 24 years later (and who’s reunited for another show) – Yahoo

    Why Taylor Swift Name-Dropped Elizabeth Taylor in Her New Album – Yahoo

    Here’s Why Taylor Swift Dropped Elizabeth Taylor’s Name in Her New Album

    Al Roker Gives Olivia Dean an Unexpected ‘New Job’ on the ‘Today’ Show – Yahoo

    Al Roker Shocks Olivia Dean with an Exciting New Role on the ‘Today’ Show

    Books about the arts and some haunts for a Denton October – Denton Record-Chronicle

    Uncover Artistic Treasures and Spooky Adventures to Experience in Denton This October

    Taylor Swift Releases New Album The Life of a Showgirl : Listen and Read the Full Credits – Yahoo

    Taylor Swift Releases New Album The Life of a Showgirl : Listen and Read the Full Credits – Yahoo

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Forget Cowbells. Cows Wear High-Tech Collars Now. – The New York Times

    Ditch the Cowbells: Discover the High-Tech Collars Transforming Cattle Care

    What the Recent Price Surge Means for Figure Technology Solutions After SEC Settlement – Yahoo Finance

    What the Recent Price Surge Reveals About Figure Technology Solutions Following SEC Settlement

    MAC Brings iPad Technology to Football Sidelines Across All 13 Member Schools – Sports Video Group

    MAC Brings iPad Technology to Football Sidelines Across All 13 Member Schools – Sports Video Group

    Technology Is Becoming More Important Than Humans In CX – No Jitter

    Technology Is Becoming More Important Than Humans In CX – No Jitter

    A Tech Expo Shows What China Can Make, but Not Who’ll Buy It All – The New York Times

    Inside China’s Tech Expo: Cutting-Edge Innovations Face Uncertain Demand

    Steampunk Metal Oval Technology Sense Sunglasses Personality Handmade Chain Multicolor Sunglasses UV400 – The San Joaquin Valley Sun

    Steampunk Metal Oval Sunglasses with Handmade Multicolor Chain – Bold UV400 Protection and Unique Style

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
  • Home
  • Business
  • Entertainment
    Charlie Hunnam Reflects on Playing a Serial Killer in Monster: The Ed Gein Story – Yahoo

    Charlie Hunnam Reveals the Dark Challenges of Playing a Serial Killer in Monster: The Ed Gein Story

    “Reba” cast, then and now: See the stars 24 years later (and who’s reunited for another show) – Yahoo

    “Reba” cast, then and now: See the stars 24 years later (and who’s reunited for another show) – Yahoo

    Why Taylor Swift Name-Dropped Elizabeth Taylor in Her New Album – Yahoo

    Here’s Why Taylor Swift Dropped Elizabeth Taylor’s Name in Her New Album

    Al Roker Gives Olivia Dean an Unexpected ‘New Job’ on the ‘Today’ Show – Yahoo

    Al Roker Shocks Olivia Dean with an Exciting New Role on the ‘Today’ Show

    Books about the arts and some haunts for a Denton October – Denton Record-Chronicle

    Uncover Artistic Treasures and Spooky Adventures to Experience in Denton This October

    Taylor Swift Releases New Album The Life of a Showgirl : Listen and Read the Full Credits – Yahoo

    Taylor Swift Releases New Album The Life of a Showgirl : Listen and Read the Full Credits – Yahoo

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Forget Cowbells. Cows Wear High-Tech Collars Now. – The New York Times

    Ditch the Cowbells: Discover the High-Tech Collars Transforming Cattle Care

    What the Recent Price Surge Means for Figure Technology Solutions After SEC Settlement – Yahoo Finance

    What the Recent Price Surge Reveals About Figure Technology Solutions Following SEC Settlement

    MAC Brings iPad Technology to Football Sidelines Across All 13 Member Schools – Sports Video Group

    MAC Brings iPad Technology to Football Sidelines Across All 13 Member Schools – Sports Video Group

    Technology Is Becoming More Important Than Humans In CX – No Jitter

    Technology Is Becoming More Important Than Humans In CX – No Jitter

    A Tech Expo Shows What China Can Make, but Not Who’ll Buy It All – The New York Times

    Inside China’s Tech Expo: Cutting-Edge Innovations Face Uncertain Demand

    Steampunk Metal Oval Technology Sense Sunglasses Personality Handmade Chain Multicolor Sunglasses UV400 – The San Joaquin Valley Sun

    Steampunk Metal Oval Sunglasses with Handmade Multicolor Chain – Bold UV400 Protection and Unique Style

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
Earth-News
No Result
View All Result
Home Health

Aficamten Advancing for Cardiomyopathy After SEQUOIA-HCM

May 22, 2024
in Health
Aficamten Advancing for Cardiomyopathy After SEQUOIA-HCM
Share on FacebookShare on Twitter

LISBON, Portugal — A novel oral drug offers clinically meaningful improvements in exercise capacity in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) and reduces the burden of limiting symptoms, new data from the SEQUOIA-HCM trial reveal.

Aficamten is an investigational next-generation selective cardiac myosin inhibitor that reduces left ventricular contractility. Findings from the previous phase 2 REDWOOD-HCM trial suggested that the drug leads to ” clinically relevant” decreases in pressure gradients.

Now, findings from SEQUOIA-HCM show that aficamten confers benefits across a range of measures, said Martin S. Maron, MD, director of the Hypertrophic Cardiomyopathy Center at Lahey Hospital and Medical Center in Burlington, Massachusetts, who presented the findings at the Heart Failure Association of the European Society of Cardiology 2024

The study, simultaneously published in The New England Journal of Medicine, suggests that aficamten led to clinically meaningful improvements in exercise capacity. It also “decreased the burden of limiting symptoms, based on improvements in both physician- and patient-derived metrics,” Maron said at the conference to rapturous applause.

“Robust functional and symptomatic improvements and relief of obstruction was observed early and remained durable throughout the treatment period,” he explained. “In totality, SEQUOIA-HCM underscores the clinical efficacy of aficamten in the treatment of patients with symptomatic obstructive HCM.”

SEQUOIA-HCM meets the criteria for a trial to be deemed “important,” said Perry M. Elliott, MD, PhD, professor of cardiovascular medicine and director of the Institute of Cardiovascular Science at University College London, United Kingdom.

The results show that aficamten is “effective in improving symptoms, exercise capacity, quality of life, and drug-refractory outflow tract obstruction,” he continued.

“Of course, we need long-term data to tell whether this is truly sustainable,” Elliott added. “But I think we now have two pivotal trials that, to my mind at least, mean that myosin inhibitors should now be regarded as standard of care in drug-refractory hypertrophic cardiomyopathy.”

Myosin Inhibitors for HCM

Steve R. Ommen, MD, from the Department of Medicine at the Mayo Clinic in Rochester, Minnesota, wrote in an accompanying editorial with the published study: “The availability of cardiac myosin inhibitors as a tool for symptomatic patients with HCM is a benefit.”

“Refining the appropriate role for these drugs should soon follow with more clinical experience outside the clinical trial environment,” he added, noting that “it seems prudent to continue to use widely available, easy-to-use, cost-effective agents, including beta-blockers and calcium-channel blockers, as first-line therapy in most patients.”

“If patients remain symptomatic or have side effects from these drugs, then all options should be discussed, including treatment with disopyramide or cardiac myosin inhibitors and invasive septal reduction therapy,” Ommen added.

Maron began his presentation by explaining that obstructive HCM is associated with limiting symptoms “particularly exertional dyspnea and decreased exercise capacity, which of course substantially impact a patient’s quality of life.”

Cardiac hypercontractility “is an important disease-related mechanism that’s responsible for driving LVOT [left ventricular outflow tract obstruction],” which is a primary determinant of the limiting symptoms, he said.

Because a current first-line medical therapy for obstructive HCM has “limited efficacy and important side effects,” Maron said, there is “currently an unmet treatment need.”

The pharmacologic features of aficamten offer a wide therapeutic window, with no need for serum plasma drug concentration monitoring, and allow for rapid dose adjustments, all with “minimal drug-drug interactions,” he explained.

Building on the REDWOOD-HCM trial, SEQUOIA-HCM enrolled patients with obstructive HCM who were already receiving standard-of-care therapy and randomly assigned them to standard of care plus aficamten or placebo.

Aficamten was initiated at a dose of aficamten 5 mg that could be escalated to a maximum dose of 20 mg. “Those dose escalations occurred at weeks 2, 4, and 6 and were based on echocardiographic assessment,” Maron explained.

The primary endpoint was change in peak oxygen uptake (pVO2) from baseline to week 24; among the 10 secondary endpoints was change in the self-reported Kansas City Cardiomyopathy Questionnaire (KCCQ)–Clinical Summary Score (CSS) from baseline, assessed in a hierarchical manner. 

Of the 282 study participants, approximately 40% were women, and the mean age was 59.0 years. The aficamten and placebo groups were “really well balanced,” Maron explained.

“Patients were on typical background therapy for obstructive HCM,” he reported, which included beta-blockers for slightly more than 60% of participants, calcium-channel blockers for around 30%, and disopyramide for slightly more than 10%.

The study met its primary endpoint. There was no change in pVO2 from baseline to week 24 in the placebo group, whereas there was a significant increase of 1.8 mL/kg/min in the aficamten group (P=.000002). This resulted in a least square mean between-group difference at week 24 of 1.7 mL/kg/min.

For context, previous data have “demonstrated that the risk of death or transplant is reduced by about 18% for each increase in pVO2 of 1 mL/kg/min,” so the increase seen with aficamten “far exceeds the clinically meaningful threshold for an enhancement in exercise capacity,” Maron said.

This effect was seen across “every single one of the prespecified subgroups,” including the subgroup in which patients were stratified by baseline beta-blocker use, he reported.

At week 24, aficamten was significantly better than placebo was for all 10 secondary endpoints (P <.0001 the least square mean difference in left ventricular outflow tract gradient after valsalva maneuver was mm hg least-squares kccq-css score points and of patients experienced an improvement from baseline at one new york heart association functional class.>

On exploratory analysis, patients in the aficamten group spent 78 fewer days eligible for invasive septal reduction than did patients in the placebo group (P <.0001 and experienced an reduction in n-terminal pro-b-type natriuretic peptide levels from baseline to week>

In a separate presentation of SEQUOIA-HCM data, 73.9% of patients in the aficamten group experienced at least one adverse event after starting treatment compared with 70.7% in the placebo group.

In addition, atrial fibrillation was experienced by 2.8% of patients in the aficamten group and 2.9% of patients in the placebo group, reported Caroline J. Coats, MD, PhD, School of Cardiovascular and Metabolic Health, University of Glasgow, United Kingdom. 

Palpitations were more common in the aficamten group than in the placebo group (7.0% vs 2.9%), as was hypertension (7.7% vs 2.1).

At week 24, the left ventricular ejection fraction was modestly lower in the aficamten group than in the placebo group, with a least-squares mean difference of -4.8%. 

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Medscape – https://www.medscape.com/viewarticle/aficamten-advancing-cardiomyopathy-after-sequoia-hcm-2024a10009my

Tags: AdvancingAficamtenhealth
Previous Post

FDA Approves Belimumab Autoinjector for Pediatric Lupus

Next Post

Does Your Patient Really Need a Guardian?

Air quality speed run – Washington State Department of Ecology (.gov)

Battling Pollution: Washington State’s Urgent Fight for Cleaner Air

October 6, 2025
Equity in science is a beautiful lie — and I’m done pretending – Nature

Equity in science is a beautiful lie — and I’m done pretending – Nature

October 6, 2025
Explore a bird database with 11,500 species – Popular Science

Explore an Incredible Bird Database Showcasing 11,500 Stunning Species

October 6, 2025
South Shore broker funded ‘extravagant lifestyle’ with $11.6 million taken from clients and colleagues, prosecutors say – Boston.com

South Shore broker funded ‘extravagant lifestyle’ with $11.6 million taken from clients and colleagues, prosecutors say – Boston.com

October 6, 2025
QRG Capital Management Inc. Purchases 9,519 Shares of Marvell Technology, Inc. $MRVL – MarketBeat

QRG Capital Management Takes Bold Step by Acquiring 9,519 Shares of Marvell Technology

October 6, 2025
Jaxson Dart, Cam Skattebo fumble away a Giant opportunity vs. Saints – Yahoo Sports

Jaxson Dart, Cam Skattebo fumble away a Giant opportunity vs. Saints – Yahoo Sports

October 6, 2025
‘The World Report’ of The Church of Jesus Christ of Latter-day Saints – KSL TV 5

Inside The World Report: Exploring the Impact of The Church of Jesus Christ of Latter-day Saints

October 6, 2025
Thai Airways Launches New Premium Economy on Flights From Most Visited City in the World – Aviation A2Z

Thai Airways Launches New Premium Economy on Flights From Most Visited City in the World – Aviation A2Z

October 6, 2025
Charlie Hunnam Reflects on Playing a Serial Killer in Monster: The Ed Gein Story – Yahoo

Charlie Hunnam Reveals the Dark Challenges of Playing a Serial Killer in Monster: The Ed Gein Story

October 6, 2025
Pre-rolls, education and industry optimism: Takeaways from Ohio Cannabis Health & Business Summit 2025 – Cleveland.com

Pre-rolls, Education, and Industry Optimism: Top Insights from the Ohio Cannabis Health & Business Summit 2025

October 6, 2025

Categories

Archives

October 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
« Sep    
Earth-News.info

The Earth News is an independent English-language daily published Website from all around the World News

Browse by Category

  • Business (20,132)
  • Ecology (854)
  • Economy (874)
  • Entertainment (21,748)
  • General (17,441)
  • Health (9,916)
  • Lifestyle (887)
  • News (22,149)
  • People (876)
  • Politics (885)
  • Science (16,085)
  • Sports (21,375)
  • Technology (15,855)
  • World (857)

Recent News

Air quality speed run – Washington State Department of Ecology (.gov)

Battling Pollution: Washington State’s Urgent Fight for Cleaner Air

October 6, 2025
Equity in science is a beautiful lie — and I’m done pretending – Nature

Equity in science is a beautiful lie — and I’m done pretending – Nature

October 6, 2025
  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

Go to mobile version